| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
6.37(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,969 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
138,093 |
288,980 |
461,958 |
926,280 |
| Total Sell Value |
$8,135,395 |
$19,867,810 |
$25,677,895 |
$46,442,456 |
| Total People Sold |
7 |
8 |
8 |
12 |
| Total Sell Transactions |
11 |
21 |
41 |
87 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcdowell Caryn Gordon |
GC & Chief Compliance Officer |
• – – |
2018-01-16 |
4 |
OE |
$6.37 |
$17,694 |
D/D |
2,709 |
15,625 |
|
- |
|
| Mcdowell Caryn Gordon |
GC & Chief Compliance Officer |
• – – |
2017-11-02 |
4 |
OE |
$6.37 |
$8,850 |
D/D |
1,355 |
15,000 |
|
- |
|
| Mcdowell Caryn Gordon |
GC & Chief Compliance Officer |
• – – |
2017-11-02 |
4 |
AS |
$12.90 |
$55,134 |
D/D |
(4,260) |
14,375 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2017-11-01 |
4 |
AS |
$13.10 |
$67,553 |
D/D |
(5,000) |
65,680 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2017-11-01 |
4 |
AS |
$13.05 |
$98,046 |
D/D |
(7,321) |
46,191 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2017-11-01 |
4 |
OE |
$11.10 |
$73,993 |
D/D |
6,666 |
52,234 |
|
- |
|
| Mcdowell Caryn Gordon |
GC & Chief Compliance Officer |
• – – |
2017-10-06 |
4 |
AS |
$15.20 |
$204,162 |
D/D |
(13,181) |
16,771 |
|
- |
|
| Mcdowell Caryn Gordon |
GC & Chief Compliance Officer |
• – – |
2017-10-06 |
4 |
OE |
$6.37 |
$75,352 |
D/D |
11,583 |
27,452 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2017-10-02 |
4 |
AS |
$14.40 |
$72,944 |
D/D |
(5,000) |
30,000 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2017-10-02 |
4 |
OE |
$4.02 |
$20,100 |
D/D |
5,000 |
35,000 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2017-10-02 |
4 |
AS |
$14.40 |
$72,957 |
D/D |
(5,000) |
69,885 |
|
- |
|
| Mcdowell Caryn Gordon |
GC & Chief Compliance Officer |
• – – |
2017-09-06 |
4 |
AS |
$14.10 |
$147,864 |
D/D |
(10,131) |
18,469 |
|
- |
|
| Mcdowell Caryn Gordon |
GC & Chief Compliance Officer |
• – – |
2017-09-06 |
4 |
OE |
$6.37 |
$66,521 |
D/D |
10,231 |
28,200 |
|
- |
|
| Mcdowell Caryn Gordon |
GC & Chief Compliance Officer |
• – – |
2017-09-06 |
4 |
AS |
$15.00 |
$1,500 |
D/D |
(100) |
18,369 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2017-09-01 |
4 |
AS |
$14.55 |
$73,528 |
D/D |
(5,000) |
74,885 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2017-09-01 |
4 |
AS |
$14.60 |
$73,623 |
D/D |
(5,000) |
30,000 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2017-09-01 |
4 |
OE |
$4.02 |
$20,100 |
D/D |
5,000 |
35,000 |
|
- |
|
| Costa Santo J |
Director |
– • – |
2017-08-31 |
4 |
AS |
$15.00 |
$75,000 |
D/D |
(5,000) |
0 |
|
- |
|
| Costa Santo J |
Director |
– • – |
2017-08-31 |
4 |
OE |
$4.44 |
$22,200 |
D/D |
5,000 |
5,000 |
|
- |
|
| Morgan Bradley Paul |
SVP Drug Discovery & Early Dev |
• – – |
2017-08-31 |
4 |
AS |
$15.00 |
$1,774,950 |
D/D |
(118,330) |
46,441 |
|
- |
|
| Morgan Bradley Paul |
SVP Drug Discovery & Early Dev |
• – – |
2017-08-31 |
4 |
OE |
$6.00 |
$927,943 |
D/D |
118,330 |
49,079 |
|
- |
|
| Costa Santo J |
Director |
– • – |
2017-08-29 |
4 |
AS |
$14.00 |
$70,000 |
D/D |
(5,000) |
0 |
|
- |
|
| Costa Santo J |
Director |
– • – |
2017-08-29 |
4 |
OE |
$4.44 |
$22,200 |
D/D |
5,000 |
5,000 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2017-08-29 |
4 |
AS |
$14.00 |
$70,000 |
D/D |
(5,000) |
30,000 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2017-08-29 |
4 |
OE |
$4.02 |
$20,100 |
D/D |
5,000 |
35,000 |
|
- |
|
710 Records found
|
|
Page 27 of 29 |
|
|
0.84 (1.59%) 
